Cell and Gene Commercialization
-
Rethinking CGT Biotech Growth & Investment with Audrey Greenberg
4/8/2025
On the 100th episode of Cell & Gene: The Podcast, Host, Erin Harris, sits down with Audrey Greenberg, Founder and CEO of AG Capital Advisors. Audrey is the award-winning executive, board director, and strategic advisor with a proven track record of launching, scaling, and successfully exiting multi-billion-dollar ventures.
-
4 Key Solid Tumor Therapy Objectives iPSCs Can Help Achieve
4/4/2025
Induced pluripotent stem cells offer some key biologic, technical, and financial advantages over more established PBMC-derived therapies.
-
Indian Biosimilar Companies Are Poised To Succeed In The Global Market
3/31/2025
For Indian biosimilar developers looking to capitalize on the upcoming patent cliff, it is vital to play to your strengths and identify strategies for breaking into competitive regulatory markets.
-
How The Cell And Gene Therapy Market Is Taking Shape
3/31/2025
Targeting diseases at their genetic root, cell and gene therapies offer unprecedented hope. Yet, the industry grapples with balancing groundbreaking potential against the challenge of high-priced treatments.
-
2025 Cell Therapy Outlook From BPI West
3/31/2025
Bioprocess Online and Cell & Gene spoke with Takeda’s Amy Shaw at BPI West to discuss the industry and her key takeaways from the conference.
-
A 5-Step Guide To Achieving Your Biosimilar Milestones On Time
3/24/2025
As the biologic patent cliff looms, biosimilar developers must strategically plot their approach to development and manufacturing to secure a corner of their market and reach their target patients.
-
The Future Promise Of Advanced Therapies In Ophthalmology
3/17/2025
Six years after the first approved gene therapy in ophthalmology, the field is experiencing a surge of activity. Delve into the exciting potential of advanced therapies for eye diseases.
-
Enabling Investment In Community Hospitals To Improve Patient Access
3/14/2025
Learn why enabling community hospitals to alleviate system constraints would usher a change in the future of cell and gene therapy delivery.
-
Mobilizing Community Hospitals To Improve Patient Access To CGTs
3/14/2025
The patient, product, and value chains for cell and gene therapies are far different than traditional healthcare delivery and requires new and specialized sets of capabilities at hospitals.
-
Collaboration Leads To CGT Progress At Astellas' West Coast Innovation Center
3/13/2025
Yoshi Shitaka, outgoing CSO and Richard Wilson, SVP, Primary Focus Lead (Genetic Regulation) at Astellas share how the company's West Coast Innovation Center serves as a central hub for AI, digital transformation, and more.